Human Metabolome Technologies Inc
TSE:6090
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Human Metabolome Technologies Inc
Depreciation & Amortization
Human Metabolome Technologies Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Human Metabolome Technologies Inc
TSE:6090
|
Depreciation & Amortization
¥112.2m
|
CAGR 3-Years
12%
|
CAGR 5-Years
19%
|
CAGR 10-Years
5%
|
|
|
Carna Biosciences Inc
TSE:4572
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Shin Nippon Biomedical Laboratories Ltd
TSE:2395
|
Depreciation & Amortization
¥3B
|
CAGR 3-Years
30%
|
CAGR 5-Years
20%
|
CAGR 10-Years
7%
|
|
|
Medinet Co Ltd
TSE:2370
|
Depreciation & Amortization
¥101.6m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-10%
|
|
|
CellSource Co Ltd
TSE:4880
|
Depreciation & Amortization
¥198.3m
|
CAGR 3-Years
63%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immuno-Biological Laboratories Co Ltd
TSE:4570
|
Depreciation & Amortization
¥18.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-16%
|
|
Human Metabolome Technologies Inc
Glance View
Human Metabolome Technologies, Inc. engages in the business of diagnostic technology and medical products. The company is headquartered in Tsuruoka-Shi, Yamagata-Ken and currently employs 69 full-time employees. The company went IPO on 2013-12-24. The firm operates in two segments. The Metabolome Analysis segment engages in the provision of analysis service that analyzes metabolomics of measurement samples and reports the results to customers. The Biomarker segment is engaged in the exploration of biomarkers, and the research and development of in vitro diagnostic drugs and diagnostic equipment.
See Also
What is Human Metabolome Technologies Inc's Depreciation & Amortization?
Depreciation & Amortization
112.2m
JPY
Based on the financial report for Dec 31, 2025, Human Metabolome Technologies Inc's Depreciation & Amortization amounts to 112.2m JPY.
What is Human Metabolome Technologies Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
5%
Over the last year, the Depreciation & Amortization growth was 21%. The average annual Depreciation & Amortization growth rates for Human Metabolome Technologies Inc have been 12% over the past three years , 19% over the past five years , and 5% over the past ten years .
